77.5 F
San Fernando
Wednesday, Oct 4, 2023

CHAD Closes $1.8 Million Sale

CHAD Therapeutics Inc. has closed the sale of the assets related to its transfilling oxygen business for $1.8 million. Because of the sale, the Chatsworth-based sleep disorder product manufacturer will discontinue production and sales of its transfilling oxygen products. “This transaction marks the final step in our announced plan to exit the oxygen business and focus our future efforts on the sleep disorder market,” CHAD President and CEO Earl Yager said. CHAD recently filed an application with the FDA for clearance to begin marketing the first of its sleep products. Yager believes the company can establish a niche in the sleep disorder market with the additional proprietary sleep products it has in advanced stages of development.

Featured Articles

Related Articles